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Mycobacterium (M. leprae), involves loss
of intraepidermal nerve fibers and pain re-
ceptors in clinical skin biopsies (Facer
et al., 2000). The absence of inflammatory
pain may thus result from effects of myco-
lactone on both inflammatory cells and
cutaneous nociceptors.
The mycolactone concentrations
required to stimulate AT2 receptors are
in the 3 mg/ml range (4 mmol/l), whereas
the level required to cause hyperpolar-
ization in vitro and that in the tissue after
infection are one to two orders of magni-
tude lower. Clearly, more evidence is
needed to confirm that mycolactone truly
is a bona fide AT2 receptor agonist at rele-
vant in vivo levels. It is also important to
know the exact location of the AT2 recep-
tors, and why mycolactone, despite bind-
ing to AT1 receptors, does not stimulate
these receptors. Studies with well-estab-
lished AT2 receptor agonists like C211506 Cell 157, June 19, 2014 ª2014 Elsevierand clinicopathological correlations may
help to answer these questions.ACKNOWLEDGMENTS
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Efforts to generate biologically active proteins by de novo computational design have been limited
to creating functional sites within pre-existing scaffolds. Procko et al. use an innovative com-
putational design approach coupled with in-vitro-targeted evolution to produce a potent polypep-
tide inhibitor of a viral Bcl-2-like protein. This novel inhibitor triggers apoptosis of virus-infected
cells.Metazoan organisms employ a distinct
type of programmed cell death, called
apoptosis, to eliminate severely damaged
or infected cells. The Bcl-2 gene family
encodes proteins that control apoptotic
signaling via the cell-intrinsic, mitochon-
drial pathway (Cory and Adams, 2002).
Two structural subclasses of this family
share Bcl-2 homology (BH) motifs: (1)
BH3 proteins (e.g., Bim, Bid, Bad, Bmf,Puma, and Noxa), which harbor a single
BH motif and promote apoptosis; and (2)
multi-BH proteins, which possess three
or four BH regions and act either as
apoptosis activators (e.g., Bax and Bak)
or inhibitors (e.g., Bcl-2, Bcl-xL, Bcl-w,
and Mcl-1). Some BH3 factors promote
apoptosis by sequestering prosurvival
Bcl-2 proteins from Bax and Bak,
whereas others bind directly to Bax orBak to drive activation. The BH3 motif—
an 26 amino acid a-helical peptide—
interacts with a hydrophobic groove on
the cognate binding partner.
Viruses often encode orthologs of
cellular antiapoptotic proteins to prevent
host cell death and extend viral repli-
cation. Epstein-Barr virus (EBV) latently
infects human B cells, contributing to
cancers such as Burkitt’s lymphoma.
Figure 1. Schematic Overview of the Fold From Loops Computa-
tional Design Procedure as Applied to Generation of the BHRF1
InhibitorEBV encodes a Bcl-2-like
decoy, called BHRF1, which
blocks host-cell apoptosis
(Henderson et al., 1993).
Although small-molecule in-
hibitors of Bcl-2 proteins are
being developed in the clinic
(Billard, 2013), polypeptide
inhibitors might have differen-
tiating qualities; however,
computational efforts to
design biologically active
proteins, including Bcl-2 in-
hibitors, have been limited
(Fleishman et al., 2011;
Procko et al., 2013). In this
issue of Cell, Procko et al.
(2014) employ a compu-
tational design method (Cor-
reia et al., 2014), combined
with in-vitro-directed evolu-
tion, to generate a potent
and selective polypeptide in-
hibitor of BHRF1 (Procko
et al., 2014).
The computational design
procedure developed by
Procko et al. (2014) (Fig-
ure 1)—dubbed Fold From
Loops (FFL)—requires as
input the structure of a func-
tional motif and a template
scaffold topology that will
‘‘fold’’ around this motif and
stabilize it. Procko et al.
(2014) select the Bim-BH3helix from the BHRF1:Bim-BH3 cocrystal
structure (Kvansakul et al., 2010) as the
functional motif and folding nucleus.
Structural homologs of the three-helix
bundle target scaffold—a domain
derived from a bacterial ribosome-recy-
cling factor—are then assembled around
the functional motif using a fragment-
based approach. Subsequently, they
perform multiple rounds of sequence
minimization and design. The template
scaffold guides the assembly of the
unique sequences through both atom-
pair distance constraints and topology.
They then select 1,000 structures pos-
sessing the lowest energy from an
ensemble of 5,000 FFL-assembled
homologs and align them to the Bim-
BH3 peptide in the BHRF1:Bim-BH3
complex. The interface residues outside
the Bim-BH3 motif in the docked struc-
tures are optimized using ROSETTA(Leaver-Fay et al., 2011), and the designs
are filtered for interface quality and
monomer stability. Ultimately, the au-
thors test the 74 designs with the lowest
number of buried, unsatisfied hydrogen-
bonding atoms in the unbound monomer
in a yeast display system. Of these, two
variants bind BHRF1 with apparent Kd
values of 60 nM. Notably, the best
computational predictor of binding activ-
ity is the degree of similarity between the
conformations predicted ab initio and the
designed structure. BHRF1 binders are
further optimized for affinity, specificity,
and stability via directed evolution by
yeast display to yield a stable, high-affinity
(Kd = 220 pM) variant named BINDI.
Other methods seeking to constrain
conformations of functional protein motifs
include stabilizing the helical arrangement
of BH3 peptides by covalently linking
pairs of residues on one face of the a helixCell 157, June 19,(Azzarito et al., 2013). The de
novo design approach pre-
sented by Procko et al.
(2014) has one important rela-
tive advantage: the stabilizing
protein scaffold provides
favorable interactions with
the target in addition to
those provided by the func-
tional peptide motif itself.
Indeed, the crystal structure
of the BHRF1:BINDI complex
shows that the incorporated
Bim-BH3 motif contributes
only 40% of the total
BHRF1-interaction surface.
Importantly, directed evolu-
tion of the designed scaffold
improves stability, further
enhancing affinity.
The de novo computational
design of a protein that
binds tightly and selectively
to the surface of a target and
exerts a specific biologic
activity is an important and
exciting advance—it im-
proves substantially over pre-
vious approaches of trans-
planting functional binding
epitopes into an existing pro-
tein scaffold. Upon modifica-
tion to facilitate intracellular
entry, Procko et al. (2014)
find that their inhibitor induces
apoptosis of EBV-infectedcells. Moreover, on further modification
to enable systemic delivery, they observe
that the inhibitor attenuates tumor growth
and extends host survival in a mouse
xenograft model of EBV-positive human
lymphoma. This represents the success-
ful design of an entirely novel protein
inhibitor with a meaningful, on-target
biologic activity.
In future studies, it will be interesting
to explore whether this strategy can be
applied to diverse types of protein
interactions with different template scaf-
folds. A remaining key challenge is the
development of clinically viable methods
for intracellular or systemic (preferably
nonimmunogenic) delivery of designer
proteins. Assessing whether the new
approach can be employed not only
for functional modulation but also
for wider tasks, such as payload
delivery of chemotherapeutics or other2014 ª2014 Elsevier Inc. 1507
biologically active compounds, will also
be important.
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